

Lithium is a classic, primary treatment for bipolar disorder that has paradoxically been used less over time, especially in North America, which goes against the accumulating evidence for its efficacy. Bipolar disorder is increasingly conceptualised as a chronic, potentially progressive condition worsened and accelerated by each mood episode, which might resemble multiple sclerosis or rheumatoid arthritis as a condition that requires disease-modifying treatments to change illness trajectory. In this Personal View, we argue that lithium acts like a disease-modifying drug in bipolar disorder.
Psychiatry
|15th Jan, 2026
|The Lancet
Psychiatry
|15th Jan, 2026
|The Lancet
Psychiatry
|15th Jan, 2026
|The Lancet
Psychiatry
|15th Jan, 2026
|The Lancet
Psychiatry
|15th Jan, 2026
|The Lancet
Psychiatry
|15th Jan, 2026
|The Lancet
Psychiatry
|15th Jan, 2026
|The Lancet